History
of MorphoSys

Company founded in Martinsried/Munich, Germany

First commercial partnership with Pharmacia-Upjohn

Move to the Innovation and Start-up Center for Biotechnology (IZB) Martinsried

IPO at the Frankfurt Stock Exchange

Start of an extensive partnership with Bayer AG

Presentation of the HuCAL antibody library

First HuCAL patent granted

Presentation of the HuCAL GOLD antibody library

Start of a strategic partnership with Schering AG

MorphoSys achieves a settlement of the CAT patent dispute

Dr. Simon E. Moroney receives the Bundesverdienstkreuz am Bande (Cross of the Order of Merit of the Federal Republic of Germany)

Start of a partnership with Pfizer

HuCAL antibodies to combat Alzheimer’s produce positive preclinical results

Start of a strategic partnership with Novartis

Presentation of the new research antibodies division, Antibodies by Design

Inclusion in the technology index TecDAX

MorphoSys achieves break even

The first HuCAL antibodies used in clinics

Acquisition of Biogenesis Group strengthens the research segment

First partnership with a Japanese pharmaceutical group

Acquisition of Serotec Group further strengthens the research segment

HuCAL antibodies to combat Alzheimer’s disease are used in clinics

MorphoSys announces development of new antibody platform technology

MorphoSys and Novartis forge one of the industry’s largest pharma-biotech R&D collaborations

First proprietary therapeutic antibody MOR103 enters clinical trials

MorphoSys unveils new antibody library, HuCAL PLATINUM 

First HuCAL antibody enters phase 2 clinical trials

MorphoSys signs first infectious disease alliance with Daiichi-Sankyo

First proprietary therapeutic antibody in a patient setting

First in-licensing of a clinical antibody from Xencor

Aquisition of Sloning BioTechnology

MorphoSys presents new antibody technology arYla

MOR202 enters clinical development

MorphoSys presents new antibody technology Ylanthia

MorphoSys signs first industrial biotechnology alliance with Novozymes

MorphoSys announces positive clinical data for MOR103 in RA and MOR208 in CLL

With gantenerumab from Roche, the first partnered antibody program reaches late stage development

MorphoSys celebrates its 20th anniversary

MorphoSys signs first Ylanthia-based therapeutic partnership

MorphoSys completes sale of AbD Serotec to Bio-Rad

MorphoSys signs license agreement with GlaxoSmithKline for MOR103 program

MorphoSys signs strategic alliance with Celgene for MOR202 program

MorphoSys collaborator Novartis starts pivotal study with bimagrumab

MorphoSys and Merck Serono enter strategic immuno-oncology collaboration

MorphoSys and Emergent BioSolutions sign license agreement to co-develop and commercialize prostate cancer drug candidate MOR209/ES414

MorphoSys and Emergent BioSolutions announce the beginning of a joint clinical phase 1 trial of MOR209/ES414 in patients with metastatic, castration-resistant prostate cancer (mCRPC).

MorphoSys licensee Janssen submits an application seeking approval of guselkumab for the treatment of moderate to severe plaque psoriasis in the US (FDA) and Europe (EMA).

MorphoSys moves to new company headquarter in Semmelweisstraße in Planegg.

MorphoSys celebrates its 25th anniversary.
MorphoSys's licensee Janssen received approval for Tremfya(R) (guselkumab) for the treatment of moderate-to-severe plaque psoriasis in the U.S., Europe and Canada.

MorphoSys's receives FDA breakthrough therapy designation for its proprietary lymphoma antibody MOR208 for the treatment of R/R DLBCL.

MorphoSys IPO at Nasdaq